October 25, 2011
Immuno-Biological Laboratories (IBL) announced on October 24 that it has signed a licensing contract with Ventana Medical Systems, Inc. of the US, for the Napsin A monoclonal antibody, which is used to identify the type of lung cancer. Ventana, a...read more